1Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med, 2008, 359(3):242-251.
2Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation, 2010, 89(9) : 1095-1102.
3Rose ML, West LJ. Accommodation: does it apply to human leukocyte antigens?. Transplantation, 2012, 93 (3) : 244-246.
4Jordan SC, Reinsmoen N, Lai CH, et al. Novel immunotherapeutic approaches to improve rates and Outcomes of transplantation in sensitized renal allograft recipients. Discov Med, 2012, 13(70) : 235-245.
5Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes, j Am Soc Nephrol, 2012, 23(12):2061-2071.
6FehrT, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int, 2012, 25(6) :623-632.
7Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation, 2012, 94(8):775-783.
8ZhangW, Chen D, Chen Z, et al. Successful kidney transplantation in highly sensitized patients. Front Med, 2011, 5(1):80-85.
